H. Lundbeck A/S

H. Lundbeck A/S

HLUYY - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$4.37B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
H. Lundbeck A/SH. Lundbeck A/S14.51.94%14%0.20.3

Earnings Call Q3 2026

November 11, 2026 - AI Summary

Strong Q3 / 9-month momentum in core brands (growth engines) - Viepti (eptinezumab): global revenue growth +45% at constant exchange rates to DKK 4.533bn in first 9 months; demand +39.3% vs market +15.6% (outperformance driven by new patient starts, strong conversion, and persistency). - Rexulti (brexpiprazole): global revenue DKK 5.1bn, +13% at constant exchange rates; TRx demand +15.1% through Aug; AAD remains main growth driver with TRx +29%, while MDD also growing (+13.7%). 65+ segment is 37% of TRx, expanding. - Evidence of continued execution: AI/advanced analytics and expanded sales/DTC initiatives supporting mix and conversion.
Raised full-year guidance (clear forecast upgrade) - Company is raising revenue guidance to +11–12% (at constant exchange rates). - Adjusted EBITDA growth guidance raised to +15–19% (at constant exchange rates). - Key drivers of the upgrade: stronger-than-expected Viepti and partner market performance; more confidence on underlying revenue gross profit. - What could offset: guidance acknowledges uncertainty about generic competition and partner market shipment phasing going forward.
Pipeline “focus phase” success: multiple late-/mid-stage catalysts for the next scale phase - Bexicasiran (DEE; 5HT2C agonist): on track for Phase 3 topline in Q4 (as stated); program has gained Breakthrough Therapy designation; mechanism described as potentially addressing broad DEE biology (inhibitory + excitatory modulation). - Label update plan: agreed with FDA for potential switch from TID to BID post-approval; timing “up to within a year” (no exact date). Framed as particularly meaningful for pediatric adherence. - Surprise/positive: high prior open-label results cited (up to 59.3% sustained seizure reduction at 12 months in PACIFIC open-label extension). - Bucunebart (anti-PACAP; migraine prevention): Phase III start planned by end of 2026; Phase IIb PROCEED effect highlighted (-5.9 day reduction in monthly migraine days vs baseline). - Other milestones: - Amlinetug (MSA): pivotal headline results expected Q3 2027; longest interventional Phase 3 in MSA (large dataset described). - Asedebart (anti-ACTH; Cushing’s): enrollment complete; orphan designations (FDA + EC); strong UFC normalization signals described. - D1D2 agonist (Parkinson’s): Phase II enrolling; Phase Ib data described as +3.6 hours good on-time at week 6 (with off-time reduced).

Exclusive for Stockcircle Pro members

Sign upSign Up

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$4.37 Billion
Enterprise Value$9.36 Billion
Annual dividend$0.20
Dividend yield1.94%
Earnings per Share$0
Beta0.61
Outstanding Shares198,700,000

Return

Return on Equity14.32%ROE
Return on Assets7.51%
Return on Invested Capital15.17%

Valuation & Multiples

P/E Ratio14.54P/E Ratio
PEG96.41PEG
Price to Sales0.17Price to Sales
Price to Book Ratio0.15Price to Book Ratio
Enterprise Value to Revenue0.36
Enterprise Value to EBIT1.4
Enterprise Value to Net Income2
Total Debt to Enterprise0.93
Debt to Equity0.31Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About H. Lundbeck A/S

5,214 employees
CEO: Charl van Zyl

H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales. The firm primarily sp...